BioSpace News Archive

Drug Development

J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data

Johnson & Johnson on Tuesday released Phase II/III results showing its monoclonal antibody Tremfya is better than its blockbuster Stelara in terms of endoscopic outcomes in Crohn’s disease.

May 22, 2024
·
2 min read
·
Tristan Manalac
Policy

Wyden Targets Pfizer in Ongoing Pharma Tax Investigation in Letter to CEO

As part of an ongoing Senate investigation into pharma companies’ tax rates, Sen. Ron Wyden (D-Ore.) has asked Pfizer CEO Albert Bourla to explain irregularities in its reported revenues, losses and taxes paid.

May 22, 2024
·
2 min read
·
Tristan Manalac
Pheon Raises $120M in Series B to Advance ADCs for Hard-to-Treat Cancers

London-based Pheon Therapeutics will use the funds to push its three lead antibody-drug conjugate candidates through clinical proof-of-target studies.

May 22, 2024
·
2 min read
·
Tristan Manalac
Business

Big Pharma Layoffs by the Thousands: Are Bayer and BMS Harbingers of More?

Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell BioSpace.

May 22, 2024
·
4 min read
·
Tyler Patchen
Job Trends

5 Top Companies Hiring Research Associates

Looking for research associate jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.

May 22, 2024
·
1 min read
·
Angela Gabriel
Deals

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition

Days after backing out of two Ionis-partnered neuro programs, Biogen has inked a potential $1.8 billion buy of Human Immunology Biosciences and boosting its late-stage immunology pipeline.

May 22, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure

Otsuka Pharmaceuticals announced Wednesday it is ending development of drug candidate AVP-786 after failing to improve agitation associated with dementia due to Alzheimer’s disease.

May 22, 2024
·
1 min read
·
Kate Goodwin
Business

AstraZeneca Snags Option to Buy Versant’s New Obesity Biotech SixPeaks

SixPeaks Bio emerged from stealth Wednesday with up to $110 million, a deal with AstraZeneca and plans to take weight-loss candidates designed to preserve muscle mass toward the clinic.

May 22, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development

BioSpace x DIA: Navigating the Emergence of CGT Combination Products

BioSpace’s Lori Ellis discusses the risks and challenges of cell and gene therapy combination products with DIA speakers James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.

May 22, 2024
·
1 min read
·
Lori Ellis
Policy

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for Descartes-08 for the treatment of myasthenia gravis.

May 22, 2024
·
6 min read